Skip to content
Peptide research

Pinealon

Also known as EDR Tripeptide · EDR
Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

What it is

A synthetic tripeptide (Glu-Asp-Arg) bioregulator that targets the pineal gland, marketed for neuroprotection, memory, and anti-aging. The evidence is weak: benefits rest almost entirely on cell and animal work from a single research lineage, and the few human claims (cognition after brain injury) are low-confidence. There is essentially no human safety data, and most supply is research-grade material of uncertain purity. Not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Neuroprotection via antioxidant activity and suppression of reactive oxygen species

    Low

    Dose-dependent ROS reduction in several cell types and two rat studies, no human data yet.

  • Prevention of dendritic spine loss in Alzheimer's disease models

    Speculative

    Culture experiments and a live-mouse 5xFAD study reported spine effects; human benefit remains unproven.

  • Increased serotonin expression in young rat cortical cultures; proposed epigenetic mechanism

    Speculative

    Serotonin expression increased significantly in young cortical cultures; the old-culture increase was nonsignificant. The mechanism was modeled.

Evidence limits

Evidence Level
Limited Evidence

The clinical evidence for Pinealon is limited but consistent across multiple experimental models. The strongest human evidence comes from a clinical study in 72 patients with traumatic brain injury consequences showing improved memory, cognitive function, and emotional stability with oral Pinealon added to standard therapy. A second human study in 32 elderly patients with organic brain syndrome demonstrated geroprotective effects on biological aging markers. Neither study was a randomized, double-blind, placebo-controlled trial by modern Western standards. Preclinical evidence is stronger and more mechanistically detailed: Pinealon prevents dendritic spine loss in 5xFAD Alzheimer's model neurons (71% increase in mushroom spines), suppresses ROS accumulation dose-dependently, stimulates serotonin expression through epigenetic regulation of tryptophan hydroxylase, and protects against hypoxia-induced neurodegeneration. The major limitations are: Khavinson-group origin for nearly all studies, small sample sizes, lack of independent replication, and absence of formal clinical development outside Russia.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • All safety data from Khavinson-affiliated research groups with small samples

    High
  • Upregulates serotonin synthesis (theoretical serotonergic interaction)

    Theoretical
  • Modulates neuronal excitability via NMDA/ERK pathways

    Theoretical
  • Research-grade product not made to pharmaceutical standards

    High
  • Pregnancy/breastfeeding listed as contraindications

    Moderate
  • Mild headaches, dizziness, GI discomfort reported

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.